"Thank God it's Gottlieb" was one analyst’s reaction to the news that US President Donald Trump was to pick industry veteran and former Food and Drug Administration deputy commissioner Scott Gottlieb to lead the agency.
Mr Gottlieb, a GlaxoSmithKline (LSE: GSK) adviser and board member of several small pharmaceutical companies, is seen as a safe pair of hands by the industry.
Some were concerned about a more radical and potentially disruptive choice, such as libertarian investor Jim O'Neill, who has previously argued drugs should be approved purely on the basis of their safety profile.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze